Current medication other than oral contraception,that is considered by the investigator as a reason for exclusion.
Iota carrageenan covid trial#
The subject has received any investigational drug or participated in a clinical trial within 4 weeks of entry to this study.It can be used to form kappa as well as iota carrageenan that majorly find applications in food products By product type, the kappa carrageenan segment is expected to register the highest CAGR in terms of revenue over. The subject is related to any study personnel or has any other close ties or conflicts of interest with the study sponsor. 6 hours ago &0183 &32 The company stated that this product can be used as a preventive measure for COVID-19.Known hypersensitivity or allergy to any component of the test product.Specific exclusions are asthma, immune deficiency, autoimmune disease, clinically significant cardiovascular, endocrinological, neurological, respiratory, gastrointestinal disease or any disease that is considered by the investigator as a reason for exclusion. Additionally, any other clinically significant disease that could interfere with participation in the study, with the intervention being studied, or with the evaluation of symptoms. Further research on nasal iota-carrageenan is warranted. Subjects who demonstrate respiratory and/or cardiac instability that is considered by the investigator as a reason for exclusion. Given that carrageenan has an effect on diverse virus groups, and effects at the clinical level on two old coronaviruses, it seems plausible that carrageenan may have an effect on COVID-19.Patients with predominantly extrapulmonary COVID-19 symptoms (e.g.offers Iota Carrageenan PA-2 that can be specifically used. Persistent hypoxemia with SpO2 6LO2/min at screening. The company stated that this product can be used as a preventive measure for COVID-19.Patient agrees to refrain from taking other carragelose products (e.g.Peripheral capillary oxygen saturation (SpO2) ≥ 90% on room air or supplemental oxygen at screening.Patients with respiratory COVID-19 symptoms.Hospitalized patients with PCR confirmed SARS-CoV-2 infection and symptom onset ≤ 10 days before randomization.Written informed consent obtained before any trial related procedures are performed.Why Should I Register and Submit Results?.
0 kommentar(er)
